Therapeutic Goods Administration

From Wikipedia, the free encyclopedia

The Therapeutic Goods Administration or TGA is the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia. It is a Division of the Australian Department of Health and Ageing established under the Therapeutic Goods Act 1989 (Cth). The TGA is responsible for conducting assessment and monitoring activities to ensure that therapeutic goods available in Australia are of an acceptable standard and that access to therapeutic advances is in a timely manner.

1 TGA Branches
2 TGA Expert Advisory Committees
3 Trans-Tasman harmonisation
4 See also
5 External links

[edit] TGA Branches

The TGA is divided into a number of Branches, including:

Drug Safety and Evaluation Branch (DSEB), responsible for regulating prescription medicines
Non-prescription Medicines Branch (NPMB), responsible for regulating over-the-counter and complementary medicines
Office of Devices, Blood and Tissues (ODBT)
Office of the Gene Technology Regulator (OGTR)

[edit] TGA Expert Advisory Committees

The TGA is supported in its work by a number of external expert advisory committees, including:

Australian Drug Evaluation Committee (ADEC) - for prescription medicines
Adverse Drug Reactions Advisory Committee (ADRAC)
Medicines Evaluation Committee (MEC) - for over-the-counter medicines
Complementary Medicines Evaluation Committee (CMEC) - for complementary medicines
Therapeutic Devices Evaluation Committee (TDEC) - for medical devices
National Drugs and Poisons Scheduling Committee (NDPSC)
Therapeutic Goods Committee (TGC)

[edit] Trans-Tasman harmonisation

The governments of Australia and New Zealand are currently working towards establishing a Trans-Tasman joint agency for the regulation of drugs and therapeutic goods to replace the TGA and New Zealand's Medsafe.